Probiotic effects on inflammatory bowel disease

被引:117
作者
Sheil, Barbara
Shanahan, Fergus
O'Mahony, Liam [1 ]
机构
[1] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland
[2] Natl Univ Ireland Univ Coll Cork, Dept Med & Microbiol, Cork, Ireland
关键词
D O I
10.1093/jn/137.3.819S
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Components of the commensal flora, including Bifidobacteria and Lactobacilli, have been associated with beneficial effects on the host. These beneficial effects include maintenance of intestinal homeostasis, competitive exclusion of pathogens, production of antimicrobial compounds, promotion of gut barrier function, and immune modulation. Probiotics currently can be administered in dairy yogurts and drinks and also in the form of sachets or capsules. Although preliminary studies are clearly promising, placebo-controlled, randomized, double-blind clinical trials are required to clarify the role of probiotic bacteria in the treatment of inflammatory bowel disease. The choice of probiotic bacteria, the optimal dose, mode of administration, and duration of therapy still need to be established. Detailed strain characterization is also required for all potential probiotic strains. As evidence accumulates to suggest a breakdown in tolerance toward ubiquitous intestinal bacteria, it appears logical to intervene by modulating the enteric flora. Increasingly, research suggests that probiotics may offer an alternative or adjuvant approach to conventional therapy by altering the intestinal microflora and modulating the host immune system.
引用
收藏
页码:819S / 824S
页数:6
相关论文
共 56 条
[1]   The indigenous gastrointestinal microflora [J].
Berg, RD .
TRENDS IN MICROBIOLOGY, 1996, 4 (11) :430-435
[2]   Animal models of mucosal inflammation and their relation to human inflammatory bowel disease [J].
Blumberg, RS ;
Saubermann, LJ ;
Strober, W .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (06) :648-656
[3]   Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan [J].
Bonen, DK ;
Ogura, Y ;
Nicolae, DL ;
Inohara, N ;
Saab, L ;
Tanabe, T ;
Chen, FF ;
Foster, SJ ;
Duerr, RH ;
Brant, SR ;
Cho, JH ;
Nuñez, G .
GASTROENTEROLOGY, 2003, 124 (01) :140-146
[4]   Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study vs mesalamine. [J].
Campieri, M ;
Rizzello, F ;
Venturi, A ;
Poggioli, G ;
Ugolini, F ;
Helwig, U ;
Amadini, C ;
Romboli, E ;
Gionchetti, P .
GASTROENTEROLOGY, 2000, 118 (04) :A781-A781
[5]  
Contractor NV, 1998, J IMMUNOL, V160, P385
[6]   Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum [J].
D'Haens, GR ;
Geboes, K ;
Peeters, M ;
Baert, F ;
Pennickx, F ;
Rutgeerts, P .
GASTROENTEROLOGY, 1998, 114 (02) :262-267
[7]  
Dianda L, 1997, AM J PATHOL, V150, P91
[8]   Lactobacillus GG prevents recurrence of colitis in HLA-B37 transgenic rats after antibiotic treatment. [J].
Dieleman, LA ;
Goerres, MS ;
Arends, A ;
Sprengers, D ;
Varney, RL ;
Harmsen, HJ ;
Sartor, RB .
GASTROENTEROLOGY, 2000, 118 (04) :A814-A814
[9]  
Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448
[10]  
Dunne C, 2001, AM J CLIN NUTR, V73, p386S, DOI 10.1093/ajcn/73.2.386s